Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis. Alltrna focuses on a mutation-driven approach.

Disease 80

Disease Treatment Engineering Protein Production 80

The Pharma Data

JUNE 11, 2025

Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. This mechanism has the potential to partially restore UBE3A protein production in neurons, addressing the root cause of the disorder. Source link

Trials 40

Trials Therapies Treatment Disease 40

Drug Target Review

NOVEMBER 1, 2023

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. With all these diverse methods we characterise protein-ligand interactions in many ways.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

DECEMBER 22, 2020

.] “EME aims to discover medium sized molecular bio-drugs with new modalities using its proprietary VHH technology. We will leverage this financing to accelerate collaborative research with pharmaceutical manufacturers and internal research using its own pipeline. We support companies that lead regional vitalization.

Engineering 52

Engineering Pharmaceuticals Drugs Protein Production 52

Agency IQ

APRIL 12, 2024

For example, in describing how potency should be demonstrated for CGT products, the 2011 guidance simply stated that potency for gene therapy products is derived from “at least two biological activities for its potency: the ability to transfer a genetic sequence to a cell; and the biological effect of the expressed genetic sequence.”

Production 40

Production FDA Therapies Biochemical Assays 40

Drug Target Review

MARCH 15, 2024

Transposon technologies are gaining traction due to their accuracy in integrating the gene of interest into the host genome, making them an important tool for accelerating large molecule drug development. Anis works within the strategy group in Life Sciences at Revvity, Inc. Budge JD, Knight TJ, Povey J, et al. Biotechnol Prog.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52